MAPT and Alzheimer disease: Comparing CSF biomarker levels between mild AD and aMCI in the AD continuum, we observed that, regarding t‐Tau protein levels, the mild AD group showed higher levels than the aMCI group and aMCI Aβ42/t‐Tau levels were higher than the mild AD group, as shown Table 1.